NCT01067053Unknown2 期
A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment
Grupo Espanol Multidisciplinario del Cancer Digestivo15 个研究点 分布在 1 个国家目标入组 69 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 69
- 试验地点
- 15
- 主要终点
- Time to progression
研究概览
简要总结
The purpose of this study is to determine whether bevacizumab, capecitabine and oxaliplatin are an effective and safe first line of treatment for elderly patients with metastatic colorectal adenocarcinoma.
详细描述
The efficacy will be determined by objective response rate following RECIST criteria.
In several clinical trials with Bevacizumab, there has been demonstrated that elderly patients benefits as well as the younger of a combination therapy with chemotherapy plus Bevacizumab, but these results have come from subgroup analyses of trials not specifically design to test the effect of these combinations on the elderly. This clinical trial is specific only for elderly patients and we expect to confirm the benefits demonstrated in other clinical trials where the elderly patients were a number reduced.
This clinical trial includes 3 substudies:
- Assessment of tumor response of CRC liver metastases to treatment with Avastin in combination with Capecitabine and Oxaliplatin as first line treatment by dynamic ultrasound contrast.
Main objective: Assess the performance of dynamic contrast ultrasonography (CEUS, Contrast Enhanced UltraSound) with quantification of tumor perfusion in the evaluation of tumor response of liver metastases of colorectal carcinoma to treatment with Avastin in combination with Capecitabine and Oxaliplatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Age ≥ 70 years.
- •Histologically confirmed carcinoma of the colon and/or rectum.
- •Metastatic disease non suitable for radical surgery.
- •At least one measurable metastatic lesion (as per RECIST criteria). The index lesion must not be in a previously irradiated area.
- •Non prior chemotherapy for metastatic disease. Adjuvant (or neo-adjuvant for rectal cancer patients) chemotherapy allowed if completed ≥ 12 months before inclusion.
- •Life expectancy more than 3 months.
- •Adequate renal function: creatinine ≤ 1.5 x UL and calculated creatinine clearance ≥ 30 mL/min.
- •Adequate level function: AST and ALT ≤ 2.5 x UL (≤ 5 x UL if liver metastases), bilirubin ≤ 1.5 x UL.
- •Adequate haematological function: Hb ≥ 9 gr/dl, neutrophils ≥ 1,5 x 109 /l and platelets ≥ 100000 x 109/l.
- •Urine dipstick for proteinuria < 2+. If urine dipstick is ≥ 2+, 24 hour urine must demonstrate ≤ 1 g of protein in 24 hours.
- •No clinical evidence or history of metastatic CNS disease.
- •No prior Bevacizumab treatment.
排除标准
- •Patients who previously received bevacizumab.
- •Prior chemotherapeutic treatment for metastatic CRC.
- •Prior treatment with monoclonal antibodies.
- •Clinical evidence of brain metastases or history or evidence upon physical examination of CNS disease unless adequately treated.
- •Past or current history (within the last 5 years prior to treatment start) of other malignancies except metastatic colorectal cancer (Patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).
- •Clinically significant cardiovascular disease, for example CVA (≤ 6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2, CHF, arrhythmia requiring medication, or uncontrolled hypertension.
- •Intestinal occlusion/subocclusion.
- •Chronic diarrhea.
- •Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study.
- •Known hypersensitivity to any of the study drugs.
- •Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (> 325 mg/day) or other NSAID.
- •Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic (as opposed to prophylactic) purposes. Patients receiving (or considered candidate to receive) anticoagulants agents as prophylaxis of cardiovascular risk, should continue (or start) the appropriate treatment at study entry.
- •History of venous thromboembolic or haemorrhagic events within 6 months prior to treatment.
- •Patients with previous of arterial thromboembolic event.
- •Evidence of bleeding diathesis or coagulopathy.
- •Serious, non healing wound, ulcer, or bone fracture.
- •Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment, or anticipation of the need for major surgery during the course of the study.
- •Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
- •Patients of childbearing potential not willing to use effective means of contraception.
- •Positive HIV serology.
- •Known addiction to alcohol or other drugs.
- •Patients included in other clinical trial
研究组 & 干预措施
bevacizumab, capecitabine, oxaliplatin
Experimental
6 cycles (3 weeks each one) of:
- bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.
- capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.
- oxaliplatin: 130/mg/m2(iv),1st day of each cycle.
After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine
干预措施: bevacizumab, capecitabine, oxaliplatin (Drug)
结局指标
主要结局
Time to progression
时间窗: 3 years
次要结局
- Safety of treatment according to the number of adverse events reported(3 yeras)
- Overall survival(3 years)
- Objective response rate following Response Evaluation Criteria In Solid Tumors (RECIST) criteria(3 years)
- Overall response rate(3 years)
- Number of treatment cycles administered(3 years)
- Number of patients who have required dose reductions of either drug(3 years)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder CancerBiliary Tract CancerGallbladder AdenocarcinomaNCT00142480Massachusetts General Hospital8
终止
2 期
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast CancerBreast CancerNCT00536939Eli Lilly and Company2
已完成
2 期
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01024504Hellenic Oncology Research Group46
终止
2 期
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00976677National Cancer Institute (NCI)10
已完成
2 期
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon CancerMetastatic Colorectal CancerNCT00378066Asan Medical Center49